The panel discusses the current standard of care for patients with head and neck cancer who need surgery, the findings of the Keynote 689 study, which showed improved EFS in patients with head and neck cancers treated with pembrolizumab, the RTOG 0920 study, and how it may affect their use of cetuximab in clinic, and how surgeons view the various treatment agents for head and neck cancer, and whether they prefer certain ones.

To watch the complete playlist click here